Form 4: bluebird bio Director Nick Leschly Reports Full Share Disposition Following Merger Completion

Director Nick Leschly has reported the disposition of all his direct and indirect holdings in bluebird bio, Inc. common stock and restricted stock units, effective with the completion of the company's merger into a wholly-owned subsidiary of Beacon Parent Holdings, L.P.

Summary

• Nick Leschly, a Director of bluebird bio, Inc., reported the disposition of 24,095 shares of common stock and restricted stock units (RSUs) in connection with the company's merger.
• The dispositions occurred on May 30, 2025, and June 2, 2025, as a result of the merger agreement dated February 21, 2025.
• Beacon Merger Sub, Inc., an indirect wholly-owned subsidiary of Beacon Parent Holdings, L.P., completed a tender offer for bluebird bio shares and subsequently merged with bluebird bio, Inc., effective June 2, 2025.
• Tendering stockholders had the option to receive either $3.00 in cash per share plus one contingent value right (CVR) of $6.84, or $5.00 in cash per share.
• Outstanding RSU awards were accelerated, fully vested, and converted into $3.00 in cash per share underlying the RSU plus one CVR per share.
• Following these transactions, Nick Leschly beneficially owns 0 shares of bluebird bio, Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive as it confirms the successful completion of a previously announced merger, providing liquidity and defined value for shareholders, albeit with a contingent component. For the reporting person, it's a standard disposition due to a corporate event.

Positives

• The completion of the merger provides certainty for shareholders who participated in the tender offer, allowing them to realize value for their shares.
• The acceleration and vesting of RSU awards prior to the merger's effective time allowed RSU holders to convert their awards into cash and CVRs.

Negatives

• The disposition of all shares by a director indicates the company is no longer publicly traded, which means existing public shareholders no longer have equity in the company.
• The contingent value right (CVR) component introduces uncertainty regarding the full potential payout, as it is contingent on a specified milestone.

Risks

• The contingent value right (CVR) payout of $6.84 is subject to the achievement of a specified milestone, meaning the full value is not guaranteed.
• Applicable withholding taxes will be applied to both cash and CVR payments, reducing the net proceeds to shareholders.

Future Outlook

The document primarily reports on completed transactions related to a merger and does not provide forward-looking statements or guidance regarding bluebird bio's future operations as a private entity.

Industry Context

This filing reflects the final stages of a corporate acquisition within the biotechnology sector, where a publicly traded company (bluebird bio) is taken private by an acquiring entity (Beacon Parent Holdings, L.P.). Such transactions are common in industries requiring significant capital investment and long development cycles, allowing private equity or larger corporations to streamline operations or integrate assets without public market pressures.

Comparison to Industry Standards

• Not applicable. This document reports on a specific insider transaction resulting from a merger, rather than operational or financial performance that would be compared to industry benchmarks or competitors.

Related Party Transactions

• The merger transaction itself involves Beacon Parent Holdings, L.P. and its subsidiary Beacon Merger Sub, Inc. acquiring bluebird bio, Inc., which, post-merger, makes bluebird bio a related party to Parent.

Stakeholder Impact

• Shareholders: Public shareholders of bluebird bio, Inc. have had their shares converted into cash and/or contingent value rights, ending their equity ownership in the company.
• Employees: Employees holding RSU awards have seen their awards accelerate, vest, and convert into cash and CVRs, providing a liquidity event.
• Company (bluebird bio): The company is now a private entity, operating as a wholly-owned subsidiary of Beacon Parent Holdings, L.P., which may lead to operational and strategic changes under new ownership.

Next Steps

• Shareholders who opted for the contingent value right (CVR) will await the achievement of the specified milestone for the potential $6.84 cash payment.
• bluebird bio, Inc. will continue operations as a wholly-owned subsidiary of Beacon Parent Holdings, L.P.

Key Dates

Keywords

bluebird bio, BLUE, SEC Form 4, Insider Transaction, Merger, Tender Offer, Contingent Value Right, CVR, Restricted Stock Units, RSU, Share Disposition, Corporate Action, Biotechnology, Pharmaceuticals